University of Vermont
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Vermont sits in the top decile of US sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count).
University of Vermont: 162 sponsored US clinical trials, 15 recruiting.
University of Vermont sponsors 162 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 132 completed. 5 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid-Related Disorders, with 4 trials.
Top-decile sponsor footprint
University of Vermont ranks in the top decile of sponsors by registered trial count (#183 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
132 of 141 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
162 total, page 2 of 4
Novel Arm Restraint For Critically Ill Patients To Reduce Immobility, Sedation, Agitation and Cognitive Impairment
NCT04067622
Cooking as a Health Behavior in College Students
NCT04084028
Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women
NCT04033237
Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions
NCT04049799
Personalized Pacing: A New Paradigm for Patients With Diastolic Dysfunction or Heart Failure With Preserved Ejection Fraction
NCT04721314
Physical Therapy to Treat Chronic Pain in Survivors of Trauma
NCT03933189
A Community Health Worker Program to Support Rural Older Adults
NCT03843333
Smartphone-based Financial Incentives
NCT03922360
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
NCT03922061
Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma
NCT03878654
Incentives and Case Management to Improve Cardiac Care: Healthy Lifestyle Program
NCT03759873
Examining Cooking as a Health Behavior
NCT03783962
Tele-palliative Care in Rural Dialysis Patients
NCT03744117
Novel Arm Restraint in the Intensive Care Unit
NCT03621475
Optimizing Long-Term Outcomes for Winter Depression With CBT-SAD and Light Therapy
NCT03691792
Increased Lung Volume as Controller Therapy for Asthma
NCT02953431
Performance Assessment of the PMD-200 Under General Anesthesia
NCT03467230
Piloting Visual Chat in Internet Obesity Treatment
NCT03491293
Mobile Technology to Support Physical Therapy Exercise
NCT03428893
Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors
NCT02739620
Transitional Rehabilitation in CABG Patients
NCT03892460
Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day
NCT03060083
Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
NCT03051984
The Nicotinic Cholinergic System and Cognitive Aging
NCT03408574
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
NCT02250664
Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery
NCT02945553
Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women
NCT02250534
Incentivizing Physical Activity Using Gamification, A Pilot Study
NCT02850614
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
NCT02825459
Skeletal Muscle Atrophy and Dysfunction in Human Cancer
NCT02949076
A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU
NCT02822170
Internet Assisted Obesity Treatment Enhanced With Financial Incentives
NCT02688621
PEEP as Rescue Therapy for Asthmatics With Elevated BMI
NCT02696980
Obesity Treatment Enhanced With Working Memory Training
NCT02529397
Discontinuation of Automated Engagement Support
NCT02578628
Novel Biomarkers of Thrombotic Risk
NCT02505217
Bemobile Intervention to Support Physical Activity in Cancer Survivors
NCT02824861
Financial Incentives for Smoking Cessation Among Mothers
NCT05740098
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
NCT02411357
Role of Magnesium Supplementation in the Treatment of Depression
NCT02466087
Temperature Evaluation by MRI Thermometry During Cervical Cooling
NCT02431026
Online Mind/Body Program for Fertility
NCT03343405
Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome
NCT02405832
Pre-Emptive Analgesia in Ano-Rectal Surgery
NCT02402543
Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees
NCT02172820
Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women
NCT02233673
Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women
NCT02210832
Acupuncture for Inflammatory Pain and Central Sensitization - A Pilot Study
NCT01945190
Not Quite Ready to Quit
NCT01866722
Exercise Training After an Acute Blood Clot
NCT01864447
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 26 |
| Phase 3 | 2 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the University of Vermont pipeline
15 recruiting of 162 indexed (9% open); 132 completed (81%).
Phase mix: 5 late (III/IV) vs 49 early (I/II) (early-phase heavy).
Top condition: Opioid-Related Disorders (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Vermont: open-pipeline peers nationwide
Peers matched on 162 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
University of Vermont sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 162 trials (± recruiting share)
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
- Temple University · 163 trials · 13% recruiting
- Tufts University · 163 trials · 6% recruiting
- Wayne State University · 163 trials · 13% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- Eli Lilly and Company · 9% recruiting · 1,341 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this University of Vermont page
162 registered trials is a research-attention snapshot, not an endorsement of University of Vermont or any single study.
- 15 of University of Vermont's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid-Related Disorders is the condition University of Vermont studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Vermont pipeline card: 162 registered trials from official public datasets.Report a data error.